期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Her-2/neu蛋白抑制剂在胃癌化疗中的应用 被引量：9

HER2/neu protein inhibitors in gastric cancer chemotherapy
下载PDF
导出
摘要 胃癌在世界范围内死亡率居于第二位,但其治疗尤其是进展期胃癌治疗,迄今尚无有效的标准方案。Her-2/neu蛋白是原癌基因Her-2/neu编码的一种具有酪氨酸激酶活性的跨膜糖蛋白。在胃癌的发生、发展和侵袭性转移性上发挥着重要作用。约5.6%~30%的胃癌存在Her-2/neu蛋白过度表达。Her-2/neu蛋白过度表达与胃癌患者生存期相关,可作为预后因素。各种体内体外的临床前期试验表明抗Her-2/neu治疗的有效性,多种设计不同的临床试验也证实了抗Her-2/neu蛋白治疗在胃癌化疗中的潜力。 Gastric cancer is the second leading cause of cancer mortality in the world and its management, especially in advanced stages, has evolved relatively little. In particular, no targeted modality has so far been incorporated to its treatment armamentarium. HER2/neu proto-oncogene HER2/neu protein is encoded in a kind of tyrosine kinase activity transmembrane glycoprotein. In the gastric cancer occurrence,development and invasive metastatic play an important role. About 5.6% to 30% of the HER2/neu protein overe^pression in gastric cancer exists. Overexpression of HER2/neu protein in patients relative to gastric cancer-related survival, can be used as prognostic factor. A variety of pre-clinieal in vivo and in vitro tests showed the efficacy of anti-HER2/neu, and a variety of different clinical trials also confirm the potential of anti-HER2/neu protein in gastric cancer chemotherapy.
作者 田晓云 孙国平
机构地区 安徽医科大学第一附属医院肿瘤内科
出处 《安徽医药》 CAS 2010年第4期467-470,共4页 Anhui Medical and Pharmaceutical Journal
关键词 HER-2/NEU 胃癌 Her-2/neu抑制剂 赫赛汀 HER2/nen gastric cancer HER2 prognostic factor trastuzumab
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1E.Van Cutsem, Y. Kang, H. Chung, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [ J]. Journal of Clinical Oncology( Meeting Abstracts) ,2009,27 : LBA4509.
  • 2Singleton TP, Strickler JG. Clinical and pathologic significance of the C-erbB-2(Her-2/neu) oneogene [ J 1 , Pathol Annu, 1992,27 : 165 - 190.
  • 3Shih C,Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas as introdueed into mouse fibroblasts [ J]. Nature, 1981,290:261 - 4.
  • 4Semba K, Kamata N, Toyoshima K, et al. A V-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinomn[J]. Proc Natl Acud USA, 1985,82:6497 - 501.
  • 5Coussens L, Yang-Feng TL, LiaoTe, et al.Tyrosine Kinase receptor with extensive homolog to EGF receptor share chromosomal location with neu oncogene[J].Science, 1985,230 : 1132 - 9.
  • 6Schechter AI, Hung M-C, Vaidyanathan L, et al. The neu gene: an erbB-bomologous gene distinct from and unlinked to the gene encoding the EGF receptor[ J ]. Science, 1985,229:976 - 8.
  • 7A. Marx, L. Tharun,J. Muth, et al. HER-2 amplification is highly homogenous in gastric cancer [J].Human Pathology, 2009,40 ( 6 ) : 769 - 77.
  • 8M. Kim,E. Jung, H. Lee, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction [ J ]. Human Pathology,2009,38 ( 9 ) : 1386 - 93.
  • 9Fernando K Cirne-Lima,Aline de Souza Rosa, Jane M U Kulczynski, et al. Immunobistochemical expression of HER-2/NEU-CERBB-2 in patients with adenocarcinoma of the stomach [ J ]. Rev. Col. Bras. Cir. 2009,36(2) :131 -4.
  • 10Dong IlPark, Jung WonYun, Jung Ho Park,et al. HER-2/neu Amplification Is an Independent Prognostic Faetorin Gastric Cancer[J]. Dig DisSci,2006, (51) :1371 -9.

二级参考文献16

  • 1Takashi Yao,Takashi Utsunomiya,Masafumi Oya,Kenichi Nishiyama,Masazumi Tsuneyoshi.Extremely well-differentiated adenocarcinoma of the stomach: Clinicopathological and immunohistochemical features[J].World Journal of Gastroenterology,2006,12(16):2510-2516. 被引量：19
  • 2Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis Factor-induced apoptosis via the Akt/NF-kappaB pathway[J]. J Biol Chem, 2000, 275(11) : 8027-8031.
  • 3Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3 K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis[J]. J Biol Chem, 1999, 274 (34) :24263-24269.
  • 4Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors[J]. Int J Oncol, 2004, 24(4): 893-900.
  • 5Vivanco I, Sawyers CL. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors[J]. Nat Rev Cancer, 2002, 2(7): 489-501.
  • 6Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/PTOS6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene, 2002, 21(43): 6587-6597.
  • 7Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt implications for cancer therapy[J]. Phamacol Ther, 2002, 93(2-3): 243-251.
  • 8Huang S, Houghton PJ. Targetiog mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol, 2003, 3(4): 371-377.
  • 9Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of Rapamycin/4E-Bp1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J]. Clin Cancer Res, 2004, 10(20): 6779-6788.
  • 10Yakes FM, Chinratanalab W, Ritter CA,et al. Herceptininduced inhibition of Phosphatidylinositol-3 Kinase and Akt is required for antibody-mediated effects on p27, Cyclin D1, and antitumor action[J].Cancer Res, 2002, 62(14): 4132-4141.

同被引文献98

  • 1王建红,何松,陈冬梅,谭清和,龚振夏,朱亚芳.Her-2/neu基因过表达与胃癌生物学行为的关系研究[J].临床肿瘤学杂志,2006,11(2):105-109. 被引量：4
  • 2陈斌,罗荣城,崔斐,钱新宇.胃癌HER-2/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344-347. 被引量：44
  • 3李骏白,黄瑞燕.HER-2基因过表达的乳腺癌病人内分泌治疗探讨[J].江西医药,2007,42(4):362-363. 被引量：3
  • 4李晓玲,徐建明（综述）,宋三泰（审校）.Her2-P13K-Akt信号转导通路与胃癌的关系[J].国际肿瘤学杂志,2007,34(7):502-505. 被引量：4
  • 5Ardavanis A,Kountourakis P,Kyriakou F,et al.Trastuzumab plus Paclitaxel or Docetaxel in Her-2–Negative/Her-2 ECD–Positive Anthracycline-and Taxane-Refractory Advanced Breast Cancer[J].Oncologist,2008,13:361-9.
  • 6Thureau S,Clatot F,Pillé J,et al.Prognostic value of serum level of HER-2 extracellular domain (ECD) at diagnosis of Her-2 overexpressed primary breast cancer (BC)[J].ASCO Meeting Abstracts,2009,27:e1150.
  • 7Meza-Junco J,Au HJ,Sawyer MB.Trastuzumab for gastric cancer.Cross Cancer Institute[J].Medical Oncology,Edmonton,Alberta,Canada,2009,9(12):1543-51.
  • 8Marx AH,Tharun L,Muth J,et al.Her-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2010,41(2):304-6.
  • 9Watanabe N,Miyamoto M,Tokuda Y,et al.Serum c-cerbB-2 inbreast cancer patients[J].Acta Oncol,1994,33(8):901-4.
  • 10Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin,2005,55(2) :74 - 108.

引证文献9

二级引证文献39

安徽医药
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部